Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly established Kenyan Psoriasis Registry (KPR), based at Moi Teaching and Referral Hospital in Eldoret, Kenya. In a cross-sectional analysis of 97 adult psoriasis patients enrolled in the KPR, we evaluated associations of demographic and disease characteristics with independent outcomes of dermatology-associated QoL (Dermatology Life Quality Index, DLQI), anxiety (Generalized Anxiety Disorder 7-item, GAD-7), and depression (Patient Health Questionnaire 9-item, PHQ-9). Univariate and multivariate linear regression models were used to identify associations, with P < 0.05 considered statistically significant. In univariate analyses, age, female gender, marital status, certain subethnicities, high-impact body sites, itch and pain, sleep disturbance, and disease severity were factors associated with worse QoL, anxiety, and depression scores. In multivariate analyses, younger age, Itch Numeric Rating Scale, and Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance T-score remained significantly associated with worse DLQI. Both PROMIS Sleep Disturbance and separated marital status were associated with worse GAD-7 and PHQ-9. Kenyan psoriasis patients experience significant QoL and mental health burden, with younger age, itch, sleep disturbance, and separated marital status associated with worse outcomes.

Chronic Hand Eczema (CHE) is a multifactorial, fluctuating inflammatory disease of the hands and wrists that negatively impacts patients' health-related quality of life (HRQoL). To assess the effects of delgocitinib cream versus cream vehicle on HRQoL. DELTA 1 and DELTA 2 were phase 3 trials of identical design in which adults with moderate to severe CHE were randomised (2:1) to double-blind treatment with delgocitinib cream 20 mg/g or cream vehicle twice daily for 16 weeks. Data were pooled from both trials and changes in EQ-5D, Dermatology Life Quality Index (DLQI), and Hand Eczema Impact Scale (HEIS), including the HEIS Proximal Daily Activity Limitations (PDAL) and HEIS Embarrassment (Emb) subsets, were compared. Across the two trials, 639 patients were randomised to delgocitinib cream and 321 to cream vehicle. Delgocitinib cream resulted in significantly greater improvement in EQ-5D, DLQI, HEIS, HEIS PDAL, and HEIS Emb compared with cream vehicle at week 16 (all p < 0.001). More patients achieved clinically meaningful improvement from baseline in patient-reported outcomes at week 16 (all p < 0.001), and the mean time spent in an improved HRQoL state increased with delgocitinib cream. Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101).

Post-inflammatory pigment alteration (PIPA) in skin previously affected by psoriasis is an important, often neglected problem. PIPA has a disproportionate negative impact in people with skin of color. The phase3b VISIBLE study evaluated guselkumab efficacy and safety in participants with skin of color and moderate-to-severe plaque psoriasis (cohortA) or moderate-to-severe scalp psoriasis (cohortB). Here we report results from exploratory assessments of the quality-of-life impact of pigmentation changes as psoriasis lesions resolve and long-term skin clearance is achieved and of correlations between dyspigmentation and clinical and patient-reported outcomes. Randomized (3:1) participants received guselkumab 100mg or placebo with crossover to guselkumab at week16. Patient-reported impact of dyspigmentation on quality of life was assessed via Skin Discoloration Impact Evaluation Questionnaire (SDIEQ). Correlations between SDIEQ, Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) were assessed. Pigmentation journeys were tracked using standard and cross-polarized photographs evaluated for erythema, pigmentation, and skin tone evenness. Across treatment and Fitzpatrick skin type groups (N = 205), mean SDIEQ scores decreased from 8.4-9.5 (moderate impact) at baseline to 1.3-1.9 (mild impact) at week48. Photographic improvements in pigmentation were also observed. The majority of guselkumab-treated participants achieved clear or almost clear skin at week48. In cohortA, mean percent PASI improvement from baseline was 94.9%; in cohortB mean percent Psoriasis Scalp Severity Index improvement was 94.6%. At week48, correlation between SDIEQ and DLQI (r = 0.7456; p < 0.001) was stronger than between PASI and DLQI (r = 0.3345; p < 0.001). Following treatment with guselkumab, most participants achieved clear or almost clear skin and substantial improvements in skin discoloration. Exploratory analyses showed SDIEQ improvements impacted quality of life more than PASI improvements, suggesting greater attention to PIPA is warranted in comprehensive psoriasis management, especially for patients with skin of color. NCT05272150.

Mapping the Children's Dermatology Life Quality Index Questionnaire to EQ-5D-Y-3L in Pediatric Patients With Atopic Dermatitis.

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial.

Customized Non-invasive Brachytherapy With Tailored Surface Moulds: An Experience From a Tertiary Care Centre.

Psoriasis is a chronic inflammatory disease often accompanied by musculoskeletal symptoms and psoriatic arthritis (PsA). Early identification of PsA remains challenging, underscoring the need for interdisciplinary care between dermatology and rheumatology. To evaluate the diagnostic and therapeutic impact of an interdisciplinary dermatology-rheumatology board (IDRB) for patients with psoriasis, we initiated a non-randomized, prospective bicentric study. A total of 182 patients with psoriasis were enrolled at baseline (V0), of whom 111 completed the 12-month follow-up (V2). Forty-seven (25.8%) patients participated in the IDRB, and 135 (74.2%) patients received standard dermatological care. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS-A/D), pain, systemic inflammation, psoriatic arthritis (PsA) diagnosis, and systemic therapy courses were analyzed. Group differences and changes over time were assessed using non-parametric and parametric tests, and predictors of therapy modification were explored using univariate logistic regression. Over 12 months, patients in the IDRB group showed statistically significant improvements in PASI, DLQI, and HADS-A (all p ≤ 0.05). Among participants without PsA at baseline and with complete PsA documentation at follow-up, new PsA diagnoses occurred more often in the IDRB cohort (31%) than in standard care (9.8%) (Fisher's exact p = 0.0295; χ2 p = 0.0360; OR = 4.14). In univariate analyses, higher baseline PASI, DLQI, and HADS-A values were each associated with subsequent therapy modification. Within the IDRB group, biologic treatments shifted over time toward IL-17- and IL-23-targeted agents, indicating a move toward more streamlined and targeted systemic therapy patterns compared with standard care. An IDRB may contribute to more structured PsA assessment and to more informed therapeutic decisions in patients with psoriasis. Integrating objective clinical measures together with patient-reported burden appears crucial for guiding treatment modification and optimizing outcomes. Given the non-randomized, self-selected design, these findings should be interpreted as associations. DRKS-Deutsches Register Klinischer Studien listing: DRKS00037907.

Background and Objectives: Chronic spontaneous urticaria (CSU) significantly affects patients' quality of life (QoL) and remains challenging to manage, particularly in under-researched regions. This study aimed to assess the clinical burden, disease control, and quality of life among patients with CSU in Kazakhstan and to identify predictors of severe disease activity. Materials and Methods: We conducted a cross-sectional study of 350 patients with CSU attending the Republican Allergy Center in Almaty between December 2024 and June 2025. Patients were classified based on the presence of co-existing chronic inducible urticaria (CIndU), angioedema, or both. Disease activity, control, and QoL were assessed using the Urticaria Activity Score over 7 days (UAS7), Urticaria Control Test (UCT), and Dermatology Life Quality Index (DLQI), respectively. Multivariable logistic regression and correlation analyses were used to identify predictors of severe disease and interrelationships among clinical measures. Results: Among 350 patients (mean age 43.5 ± 14.7 years; 78% female), 46.3% had CSU alone, while 53.7% had associated phenotypes. Severe urticaria (UAS7 ≥ 28) affected 30% of patients. Suboptimal disease control (UCT ≤ 11) was reported in 30%, and 30% experienced strong or very strong QoL impairment (DLQI > 10). Older disease onset (≥60 years; OR = 1.98; 95% CI: 1.02-3.81) and nighttime symptoms (OR = 1.67; 95% CI: 1.02-2.73) were independently associated with severe disease. A strong inverse correlation was observed between UAS7 and UCT (ρ = -0.71), and a positive correlation between UAS7 and DLQI (ρ = 0.66), highlighting the impact of disease activity on control and QoL. Conclusions: CSU imposes a substantial clinical and psychosocial burden in Kazakhstan. One-third of patients experience severe symptoms and impaired QoL despite ongoing treatment. Older age at disease onset and nighttime symptoms may serve as practical indicators of disease severity. These findings highlight the need for improved access to advanced therapies, systematic monitoring using validated tools, and multidisciplinary care strategies in resource-constrained settings.

Vulvar lichen sclerosus (VLS), erosive vulvar lichen planus (EVLP), and vulvar lichen simplex chronicus (VLSC) are the most common vulvar lichenoid dermatoses. They are frequently misdiagnosed in clinical practice and comparative studies among them remain limited. To analyze the clinical characteristics and quality of life (QoL) burden among these three conditions, raising awareness on these distressing vulvar diseases. This retrospective cross-sectional study analyzed clinical registration data of adult patients diagnosed with VLS, EVLP, or VLSC at a single-center vulvar outpatient department from 2017 to 2025. The vulva was divided into nine anatomical regions to identify predilection sites. QoL was evaluated using either the Dermatology Life Quality Index (DLQI) or Vulvar Quality of Life Index (VQLI). Statistical analyses were conducted using GraphPad Prism version 8.2.1. This study included a total of 1,177 patients, comprising 682 patients with VLS, 429 patients with VLSC, and 66 patients with EVLP. The predilection sites varied among three diseases: the labia minora along with interlabial sulcus in VLS; the labia majora along with interlabial sulcus in VLSC; the labia minora along with vaginal opening in EVLP. A total of 941 patients were assessed using the DLQI. The median DLQI scores were 6.0 for VLS, 7.0 for VLSC, and 7.0 for EVLP, indicating a moderate effect on QoL. The remaining 236 patients were evaluated using the VQLI. The median VQLI scores were 12.0 for VLS, 13.0 for VLSC (indicating a mild impact on QoL), and 19.0 for EVLP, reflecting a moderate impact. The most affected domains included symptoms, feelings and emotions, and future health concerns (VLS and VLSC) or sex function (EVLP). Clinicians and patients should pay more attention to vulvar lichenoid dermatoses, especially EVLP. Early diagnosis and treatment to improve clinical symptoms and relieve discomfort is essential to enhance the QoL.

Hand-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia, is a frequent and burdensome complication of several anticancer chemotherapies, negatively affecting patients' quality of life. Depending on the treatment regimen, HFS may occur in 5-89% of patients. Currently, no standard therapies are available for its management. A recently commercialized alcohol-free gel containing emollient and skin-reparative components (omental purified lipids, urea, carnosine, and bromelain; POL-Podactive gel (POL-PA; Cantabria Labs, Caronno Pertusella, Italy) has shown efficacy in treating moderate-to-severe foot xerosis. However, no data are available regarding its potential role in the management of early-stage HFS. The aim of this study was to evaluate, in a pilot open trial, the efficacy and tolerability of POL-PA gel in patients with grade 1 HFS. Twelve patients (2 men and 10 women; mean age 58 years) with grade 1 HFS induced by anticancer treatments (mainly taxanes or antimetabolites) were enrolled in a 12-week pilot study after providing written informed consent. At baseline, all participants presented mild palmoplantar erythrodysesthesia and moderate xerosis. The gel was applied twice daily to the affected areas (hands and feet), with an average daily dose of 12 fingertip units (FTU; 6 g). Efficacy endpoints included the 10-item Dermatology Life Quality Index (DLQI) and subjective pain/dysesthesia assessed using a 10-cm Visual Analogue Scale (VAS; 0 = no pain, 10 = extreme pain). Assessments were performed at baseline, week 6, and week 12. The Common Terminology Criteria for Adverse Events (CTCAE) grade was also recorded at each visit. All patients completed the 12-week study. Mean DLQI decreased from 12±6 at baseline to 8±6 at week 6 and 6±5 at week 12 (p<0.02; Wilcoxon signed-rank test). Mean VAS score improved from 5±3 at baseline to 3.7±2 at week 6 and 3.0±2 at week 12, representing a 40% reduction (p<0.0016). No worsening of CTCAE grade was observed during the study. In this pilot study, an alcohol-free gel containing emollient and reparative components demonstrated beneficial effects on pain/dysesthesia and quality of life in patients with chemotherapy-induced grade 1 HFS. Controlled, well-designed trials are warranted to further define its therapeutic potential in this clinical setting.

An international treat-to-target (T2T) consensus for atopic dermatitis (AD), encompassing clinical and patient-reported outcomes, was proposed in 2021. A revised framework of systemic drug therapy for moderate-to-severe AD was proposed by Zhao and Gao in 2022. This study aimed to evaluate the efficacy of abrocitinib and dupilumab in patients with moderate-to-severe AD in the context of the clinical and patient-reported T2T goals for AD proposed by Zhao and Gao. Data were evaluated from adults with moderate-to-severe AD who received abrocitinib (200 mg/day) or dupilumab (300 mg biweekly after a 600 mg loading dose) for 16 weeks in JADE COMPARE and 26 weeks in DARE. Data from patients who received abrocitinib 100 mg/day in JADE COMPARE were also included in this analysis. Assessments included the proportions of patients attaining 1-year T2T goals proposed by Zhao and Gao (Peak Pruritus Numerical Rating Scale score of ≤4, ≥75% improvement in Eczema Area and Severity Index [EASI] or EASI≤7, ≥75% improvement in SCORing Atopic Dermatitis [SCORAD] or SCORAD≤24, Patient-Oriented Eczema Measure score of ≤7, and Dermatology Life Quality Index score of ≤5 at Week 16 of JADE COMPARE and Week 26 of DARE. In JADE COMPARE, 226, 238, and 242 patients received abrocitinib 200 mg, 100 mg and dupilumab, respectively. In JADE DARE, 362 received abrocitinib 200 mg and 365 received dupilumab. The proportions of patients attaining the 1-year T2T goals at Week 16 of JADE COMPARE were 41.2% (200 mg), 29.5% (100 mg) and 29.0% (dupilumab); these proportions were 49.5% (200 mg) and 38.3% (dupilumab) at Week 26 of DARE. Greater proportions of patients attained the 1-year T2T improvements proposed by Zhao and Gao with abrocitinib 200 mg than with dupilumab. Early achievement of 1-year targets in many patients treated with abrocitinib suggest that target domains may necessitate re-evaluation.

Atopic dermatitis (AD) involving special areas such as the hands, head and neck, and genital region poses important therapeutic challenges owing to distinct barrier fragility, environmental exposure, and mixed Th1/Th2/Th17 activation. These sites often drive treatment escalation despite limited overall body surface involvement. Evidence on the real-world effectiveness of upadacitinib in these anatomical locations remains limited. A retrospective, observational multicenter study was conducted across five Spanish dermatology departments (November 2024 to November 2025). Adults and adolescents with moderate-to-severe AD and involvement of at least one special area treated with upadacitinib (15 or 30 mg) for ≥ 16 weeks were included. Disease severity was assessed using the Eczema Area and Severity Index (EASI), body surface area (BSA), pruritus numeric rating scale (NRS), Dermatology Life Quality Index (DLQI), Investigator's Global Assessment (IGA), and local 0-4 Physician Global Assessment (PGA). Minimal disease activity (MDA) was defined as EASI ≤ 3 plus pruritus-NRS 0-1. Descriptive statistics were applied. Distribution-shift plots were used to analyze categorical changes in special areas. Overall, 57 patients were included (mean age 47.9 ± 17.6 years, 59.6% women). Facial/neck, hand, and genital involvement were present in 73.7%, 61.4%, and 21.1% of patients, respectively; 31.9% had ≥ 2 special areas affected. Upadacitinib induced rapid improvement, with EASI decreasing from 18.9 to 2.7 at week 16 and 2.4 at week 52. MDA was reached by 61% at week 16 and 69% at week 52. Special-area PGA improved markedly across all sites. Upadacitinib provided rapid, sustained, and clinically meaningful improvement in AD involving special areas, supporting its use in anatomically sensitive areas.

Allergic contact dermatitis (ACD) is a chronic inflammatory skin disorder associated with substantial impairment in quality of life (QoL). Few studies have comprehensively assessed the multidimensional impact of ACD using validated QoL instruments and healthy controls. To evaluate the impact of ACD on QoL compared to a control group and to explore the association between clinical variables and patient-reported outcomes. This cross-sectional study included 225 patients with confirmed ACD (positive and clinically relevant patch tests) and 225 healthy controls. All participants completed the Dermatology Life Quality Index (DLQI), the EuroQoL-5D (EQ-5D-5L) and the Skindex-29. Disease severity was assessed using the modified Investigator's Global Assessment (mIGA). Statistical analyses included nonparametric Mann-Whitney U tests for between-group comparisons, correlation analyses, and multivariate linear and ordinal regression models to identify predictors of quality-of-life impairment. Patients with ACD showed significantly greater impairment across all QoL measures compared to controls (p < 0.001). Pruritus was the most frequently reported symptom (45.0%), and emotional distress and functional limitations were prominent. Higher mIGA scores were significantly associated with poorer QoL across all instruments. ACD has a marked negative impact on multiple dimensions of QoL, comparable to that observed in other chronic dermatoses. These findings underscore the importance of integrating standardised QoL assessments into the routine management of ACD and support the adoption of multidimensional approaches in both clinical evaluation and therapeutic decision-making, while also highlighting the relevance of psychosocial screening as an essential component of comprehensive patient care.

Background: With an improvement in medical services and increased life expectancy, in both developed and developing nations, the geriatric population is increasing, with the cutaneous dermatoses. Although these dermatological diseases are gaining more attention, their mental health is lagging far behind. This study is being conducted to identify the common geriatric dermatoses and also their effect on quality-of-life. The aims of this study are to study the pattern and frequency of dermatoses in patients aged 60 years and above and to assess the effect of it on their quality-of-life. Methods: In total 60 patients aged 60years and above presenting to dermatology out-patient department were recruited. Socio-demographic details, presence of co-morbidities and dermatological complaints were recorded on a data collection form. Skin diseases were categorized into 7 categories for statistical analysis. For assessing the effect of dermatoses on quality-of-life of participants, dermatology life quality index was administered. Results: 60 patients were evaluated, 64.3% were male and 35.7% were females. Mean age of patients was 67.60±6.236, 35% patients had one or more co-morbidities. Papulosquamous disorders were the commonest dermatoses seen in 31.3% patients, followed by infections and infestations in 30%. Around 20% patients had moderate to large effect on quality-of-life. Conclusions: Skin changes are amongst the most visible signs of aging. Furthermore, the basic fact of looking old has negative effect on quality of life. The special needs of elderly population must be looked into by making appropriate changes in the national health policies.

Psoriasis is a chronic inflammatory skin disease associated with significant physical and psychological burden. Tildrakizumab, an interleukin-23 p19 inhibitor, has demonstrated efficacy in treating moderate-to-severe plaque psoriasis both in clinical trials and real-world setting. However, limited data are available on the impact of the effective treatment of psoriasis on the psychological health of patients. The aim of this study was to assess changes in psychological well-being, as well as clinical and quality-of-life outcomes, in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab in routine clinical practice in Italy. This was an interim analysis (IA) of a 52-week multicenter, prospective, observational study. Adults with moderate-to-severe plaque psoriasis initiating tildrakizumab were enrolled. Endpoints focused on well-being and psychological health and included changes, from baseline to week28, in Depression, Anxiety, and Stress Scale-21 (DASS-21) scores, Dermatology Life Quality Index (DLQI), European Social Survey (ESS) items, and World Health Organization-Five Well-Being Index (WHO-5). Effectiveness was also monitored via Psoriasis Area and Severity Index (PASI), and safety via treatment-emergent adverse event reporting. A total of 115 patients were included (mean age 52.5years, 60.8% male), 102 receiving ≥ 1 dose of tildrakizumab and completing DASS-21 evaluations at baseline and week28. At week28, improvements were observed in DASS-21 subscales [depression (-2.6, 95%CI -2.0 to -1.0), anxiety (-2.3, 95%CI -2.0 to -1.0), and stress (-3.4, 95%CI -4.0 to -2.0)], accompanied by marked PASI reduction (-13.7, 95%CI -12.8 to -10.1). DLQI, ESS, and WHO-5 scores also improved. Adverse events were generally mild or moderate, with no unexpected safety signals. In this real-world IA, tildrakizumab was observed to improve the psychological well-being of patients, reflected by a reduction in all items of the DASS-21 scale and, in parallel, confirmed its effectiveness in managing physical symptoms of psoriasis, establishing its role in the holistic management of psoriasis.

Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits. To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis. The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients). Continuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab/bimekizumab-treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64. Patient-reported itching/skin pain/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years). A total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal P < .001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal P = .01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal P < .001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI = 0 and DLQI 0/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal P < .001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal P < .001). In patients entering the OLE, high P-SIM = 0 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI = 0 and DLQI 0/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab/bimekizumab-treated patients. After switching, secukinumab/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab/bimekizumab (62.2% and 63.8%, respectively). In this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab. ClinicalTrials.gov Identifier: NCT03536884.

This paper presents a clinical case of chronic atopic eczema successfully managed with individualised homoeo-pathic treatment and discusses the broader evidence and rationale for homoeopathy in the management of ecze-ma. A 28-year-old male with a 6-year history of flexural eczema (pruritic, erythematous, lichenified plaques on elbows, neck, and popliteal fossae) and marked sleep disturbance was treated at Aura Homoeopathy Clinic using a single, constitutionally indicated remedy, followed by minimal repetitions and supportive skin care. Over 6–8 months, the patient showed a substantial reduction in itching, lesion extent, and lichenification, with improved sleep and quality of life, and remained in stable remission for more than 18 months. This outcome is consistent with published case reports and series demonstrating meaningful improvements in SCORAD (Scoring Atopic Dermatitis) and Dermatology Life Quality Index (DLQI) scores following individual-ised homoeopathic therapy in atopic dermatitis. Evidence from Japanese and German cohorts, as summarised on Aura Homoeopathy’s eczema information page, also suggests that homoeopathic care may provide comparable long-term patient-perceived benefit to conventional treatment in certain populations, though larger controlled studies are required. Homoeopathy should therefore be considered a complementary modality, integrated with guideline-based skin care and medical supervision, rather than a standalone replacement for standard thera-py.ijhsr+4

Background: Contact dermatitis is a common chronic skin condition affecting quality of life (QoL). Patch testing is a key diagnostic process used in identifying allergens responsible for allergic contact dermatitis (ACD).Objective: To investigate the impact of patch testing on QoL outcomes.Methods: This IRB-approved registry included demographics, clinical findings, investigator global assessments (IGAs), and patch test results. QoL questionnaires (ACD-11, global severity and QoL assessments, Dermatology Life Quality Index [DLQI]) prior to and 2-6 months following patch testing were analyzed with Stata® software.Results: From 2018 to 2025, 1246 patients underwent patch testing and received pre-patch questionnaires; 548 patients had additional post-patch test assessments. Post-patch testing, IGA, global assessments of patients' self-reported QoL and skin severity, DLQI, aggregate and domain-specific ACD-11 assessments significantly improved (P < 0.0001). Median time to assessment was 94 days (interquartile range 77, 113). Patch patients, regardless of sex, race, ethnicity, duration of symptoms, atopic dermatitis history, total relevant allergens, number of allergens recalled, or body locations of involvement, demonstrated significant improvements in QoL (P < 0.0001). Improved IGA was associated with ACD diagnosis and younger age. 61.4% of patients correctly recalled all their culprit allergens.Conclusion: Patch testing provided benefit to patients in multiple physician and patient-reported outcome measures. Patients had a higher rate of allergen recollection than previously reported.

Abstract Objective: To evaluate the efficacy and safety of topical La Roche-Posay New B5 Multi-Effect Soothing and Repairing Cream in the treatment of skin adverse reactions related to EGFR inhibitors and capecitabine. Methods: A randomized, double-blind, controlled clinical study was conducted. From October 2024 to June 2025, 40 patients with skin adverse reactions (such as rash, hand-foot syndrome, pruritus, dryness, discoloration, and skin chapping) during anti-tumor therapy (EGFR inhibitors and capecitabine) were recruited from the First Affiliated Hospital of Nanjing Medical University. They were divided into two groups with 20 cases each. The experimental group was treated with topical La Roche-Posay New B5 Multi-Effect Soothing and Repairing Cream, while the control group was treated with topical silicone oil cream, twice daily for 8 weeks. Follow-ups were conducted before treatment and at 2, 4, 6, and 8 weeks after treatment. Efficacy was evaluated based on the improvement rate of rash grade, the improvement time of rash grade, the improvement rate of hand-foot syndrome grade, the improvement time of hand-foot syndrome grade, Visual Analogue Scale (VAS), and Dermatology Life Quality Index (DLQI). Adverse events were recorded. Repeated measures analysis of variance and chi-square test were mainly used to compare efficacy and safety. Results: A total of 40 patients participated in this clinical study, including 22 males and 18 females, with age of (54.21 ± 14.47) years. Before treatment, there were no statistically significant differences between the two groups in gender, age, rash grade, hand-foot syndrome grade, VAS score, or DLQI score (all p &amp;gt; 0.05). After 2 weeks of treatment, the improvement rates of rash grade and hand-foot syndrome grade in the experimental group were 20.00% (2/10) and 20.00% (2/10), respectively, while those in the control group were 10.00% (1/10) and 20.00% (2/10), respectively. There were no statistically significant differences between the two groups (p &amp;gt; 0.05). After 4 weeks of treatment, the effective rate (rash grade improvement rate + hand-foot syndrome grade improvement rate) in the experimental group was 65.00% (13/20), which was significantly higher than that in the control group (40.00%, 8/20, p &amp;lt; 0.05). After 8 weeks of treatment, the effective rate in the experimental group was 70.00% (14/20), which was significantly higher than that in the control group (45.00%, 9/20, p &amp;lt; 0.05). After 4, 6, and 8 weeks of treatment, the VAS and DLQI scores in the experimental group were significantly lower than those in the control group (all p &amp;lt; 0.05). Conclusion: La Roche-Posay New B5 Multi-Effect Soothing and Repairing Cream is safe and effective in the treatment of skin adverse reactions related to EGFR inhibitors and capecitabine. It can significantly improve rash and hand-foot syndrome after 4 weeks of use and can be applied clinically. Citation Format: X. Yan, Y. Liang, X. Huang, Y. Yin. A Randomized Double-Blind Controlled Study on La Roche-Posay New B5 Multi-Effect Soothing and Repairing Cream in the Treatment of Skin Adverse Reactions Related to EGFR Inhibitors and Capecitabine [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-03-15.

Objectives Prurigo nodularis (PN) is a chronic skin condition characterized by itchy nodules. Understanding the comprehensive patient perspective is essential for guiding treatment strategies. This study evaluated PN disease burden, and satisfaction with non-biologic therapies in France, Germany, Italy, and the UK. Methods A cross-sectional survey was conducted in adult patients with a self-reported diagnosis of PN. Disease burden was evaluated using worst itch numeric rating scale (WI-NRS; 0–10, higher indicates more severe), non-itch skin symptoms, EQ-5D-5L, Dermatology Life Quality Index, Patient-Reported Outcomes Measurement Information System Sleep Disturbance, Hospital Anxiety and Depression Scale, and Work Productivity and Activity Impairment. Results The survey included 165 patients with 67.3%, 30.3%, and 2.4% reporting a WI-NRS score of ≥7, 3–6, and 0–2, respectively. Less than half (45.5%) reported satisfaction with non-biologic treatments. Patients with WI-NRS ≥7 (vs. 3–6) experienced significantly more severe non-itch skin symptoms, and greater negative impacts on health-related quality of life and productivity. Conclusion Disease burden was high and satisfaction with non-biologic treatments was low. Patient-reported number of nodules did not strongly correlate with burden, suggesting that mild disease can induce high burden. Therefore, all aspects of disease should be considered to improve clinical management of PN.